Vlaeminck-Guillem V - Search Results

1

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer.

Vlaeminck-Guillem V. Vlaeminck-Guillem V. Transl Androl Urol. 2020 Dec;9(6):2483-2487. doi: 10.21037/tau-20-968. Transl Androl Urol. 2020. PMID: 33457221 Free PMC article. No abstract available.

2

Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.

Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, Ruffion A, Tilki D, Schalken J, Groskopf J, Van Criekinge W. Haese A, et al. J Urol. 2019 Aug;202(2):256-263. doi: 10.1097/JU.0000000000000293. Epub 2019 Jul 8. J Urol. 2019. PMID: 31026217

3

Urinary prostate cancer 3 test: toward the age of reason?

Vlaeminck-Guillem V, Ruffion A, André J, Devonec M, Paparel P. Vlaeminck-Guillem V, et al. Urology. 2010 Feb;75(2):447-53. doi: 10.1016/j.urology.2009.03.046. Epub 2009 Jul 8. Urology. 2010. PMID: 19586654 Review.

4

Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.

Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, Ruffion A, Crouzet S, Rimokh R, Gillet PG, Freyer G, Vlaeminck-Guillem V. Maillet D, et al. Eur Urol Oncol. 2021 Aug;4(4):609-617. doi: 10.1016/j.euo.2019.08.010. Epub 2019 Oct 31. Eur Urol Oncol. 2021. PMID: 31676281

5

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer.

Maillet D, Allioli N, Péron J, Plesa A, Decaussin-Petrucci M, Tartas S, Sajous C, Ruffion A, Crouzet S, Freyer G, Vlaeminck-Guillem V. Maillet D, et al. Among authors: vlaeminck guillem v. Cancers (Basel). 2021 Nov 29;13(23):6014. doi: 10.3390/cancers13236014. Cancers (Basel). 2021. PMID: 34885125 Free PMC article.

6

Exosomes and prostate cancer management.

Vlaeminck-Guillem V. Vlaeminck-Guillem V. Semin Cancer Biol. 2022 Nov;86(Pt 1):101-111. doi: 10.1016/j.semcancer.2021.08.004. Epub 2021 Aug 9. Semin Cancer Biol. 2022. PMID: 34384877 Review.

7

MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.

Luo Y, Vlaeminck-Guillem V, Baron S, Dallel S, Zhang CX, Le Romancer M. Luo Y, et al. Among authors: vlaeminck guillem v. J Exp Clin Cancer Res. 2021 Aug 26;40(1):270. doi: 10.1186/s13046-021-02058-7. J Exp Clin Cancer Res. 2021. PMID: 34446068 Free PMC article.

8

Additional value of PCA3 density to predict initial prostate biopsy outcome.

Ruffion A, Perrin P, Devonec M, Champetier D, Decaussin M, Paparel P, Vlaeminck-Guillem V. Ruffion A, et al. World J Urol. 2014 Aug;32(4):917-23. doi: 10.1007/s00345-014-1251-3. Epub 2014 Feb 6. World J Urol. 2014. PMID: 24500192

9

Urinary PCA3 score predicts prostate cancer multifocality.

Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A. Vlaeminck-Guillem V, et al. J Urol. 2011 Apr;185(4):1234-9. doi: 10.1016/j.juro.2010.11.072. Epub 2011 Feb 22. J Urol. 2011. PMID: 21334023

10

Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management.

Vlaeminck-Guillem V. Vlaeminck-Guillem V. Front Oncol. 2018 Jun 13;8:222. doi: 10.3389/fonc.2018.00222. eCollection 2018. Front Oncol. 2018. PMID: 29951375 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page